|1.||Maslov, L N: 10 articles (12/2009 - 01/2002)|
|2.||Pol, Olga: 7 articles (10/2014 - 01/2006)|
|3.||Leánez, Sergi: 6 articles (10/2014 - 01/2009)|
|4.||Lasukova, T V: 6 articles (12/2009 - 05/2002)|
|5.||Hervera, Arnau: 5 articles (05/2013 - 01/2009)|
|6.||Lishmanov, Iu B: 5 articles (10/2006 - 01/2002)|
|7.||Solenkova, N V: 3 articles (06/2009 - 01/2002)|
|8.||Krylatov, A V: 3 articles (06/2009 - 11/2003)|
|9.||Nagase, H: 3 articles (10/2006 - 04/2000)|
|10.||Gross, G J: 3 articles (07/2004 - 07/2003)|
09/08/2011 - "However, there were sex differences in the potency of local DPDPE in that a 10-fold higher dose of DPDPE was required in female rats to produce the level of anti-hyperalgesia achieved in male rats. "
10/01/2009 - "The local administration of DPDPE or NOC-18 alone dose-dependently inhibited the thermal hyperalgesia induced by peripheral inflammation. "
01/14/2009 - "However, following priming (15 min) with bradykinin or arachidonic acid, DPDPE produced a significant reduction in allodynia that was antagonist reversible, peripherally restricted, and exhibited a typical dose-response relationship. "
02/01/2012 - "Evidence for DOR-KOR heteromers in peripheral sensory neurons included coimmunoprecipitation of DOR with KOR, a DOR-KOR heteromer selective antibody augmented the antinociceptive effect of DPDPE in vivo, and the DOR-KOR heteromer agonist 6'-GNTI inhibited adenylyl cyclase activity in vitro as well as PGE(2)-stimulated thermal allodynia in vivo. "
02/01/2012 - "In vivo, nor-BNI enhanced the effect of DPDPE and decreased the effect of SNC80 to inhibit PGE(2)-stimulated thermal allodynia. "
|2.||Neuralgia (Stump Neuralgia)
12/01/2002 - "In the present study, we determined the role of NO in the inhibitory effect of DPDPE on ascending dorsal horn neurons in normal rats and in a rat model of diabetic neuropathic pain. "
06/15/2012 - "These findings reveal that the repeated local administration of DPDPE or JWH-015 did not induce antinociceptive tolerance after sciatic nerve injury-induced neuropathic pain. "
01/01/2003 - "Spinal endogenous NO contributes importantly to the analgesic action of intrathecal DPDPE in both normal and diabetic neuropathic pain conditions."
01/01/2003 - "Intrathecal DPDPE produces an antinociceptive effect in normal rats and a rat model of diabetic neuropathic pain. "
05/15/2000 - "DAMGO, a mu-opioid agonist, and DPDPE, a delta-opioid agonist, were highly effective in reducing neuropathic pain. "
05/01/2002 - "Addition of DPDPE to the perfusion solution in a final concentration of 0.1 mg/L and/or 0.5 mg/L 15 min before ischemia also decreased the incidence of reperfusion arrhythmias in a concentration-dependent manner. "
01/01/2014 - "In Experiment 2, DPDPE, Delt-D, Delt-Dvar, and Delt-E were infused at 15 minutes prior to ischemia. "
06/01/2009 - "Activation of delta 1-OR by DPDPE did not alter cardiac tolerance in ischemia-reperfusion either. "
04/01/2009 - "Cardioprotective and inotropic effects of selective agonists of delta1- and k1-opioid receptors (OR): DPDPE (0.1 microM/L) and U-50.488 (0.1 microM/L) were studied during 45 min global ischemia and 30 min reperfusion of the rat isolated perfused heart. "
07/01/2007 - "DPDPE administered before coronary artery occlusion or simulated ischemia-reperfusion reduced left ventricular infarct size by 54 +/- 15% or myocyte death by 26 +/- 4%, respectively. "
10/01/2014 - "Therefore, the coadministration of CoPP with local morphine, DPDPE, or JWH-015 may be a good strategy for the management of chronic inflammatory pain. "
10/01/2014 - "The results show that treatment with CoPP increased the local antinociceptive effects produced by morphine, DPDPE, or JWH-015 during chronic inflammatory pain, and these effects were blocked by the subplantar administration of SnPP, indicating the participation of HO-1 in the antinociceptive actions. "
03/01/2011 - "Uptake of taurocholate and [d-penicillamine(2,5)]-enkephalin, two established Oatp substrates, was increased in animals subjected to peripheral pain, suggesting increased Oatp1a4-mediated transport. "
04/01/2004 - "We compared behavioural responses in two models of acute thermal pain following DPDPE and deltorphin II administration by intracerebroventricular route. "
10/01/2009 - "Moreover, the co-administration of NOC-18 with DPDPE significantly increased the antinociceptive effects produced by DPDPE from 1 to 10 days of CFA-induced inflammatory pain (P < 0.05). "
01/01/2002 - "Injection of DPDPE into the RVLM strongly attenuated the somato-sympathetic reflex (approximately 50-80%) evoked in the lumbar sympathetic nerve and splanchnic sympathetic nerve by tibial nerve stimulation but had no effect on baroreceptor reflexes and chemoreceptor reflexes evoked by aortic nerve stimulation and brief hypoxia, respectively. "
12/01/2009 - "Pre-treatment of ICA cell-myocyte co-culture with the beta(2)-AR/CGRP-R antagonists increased myocyte death rate by 24 +/- 4% (P < 0.01) and abolished DPDPE-initiated myocyte protection against hypoxia/reoxygenation (re-O(2)). "
03/01/2004 - "The effects of the specific opioid agonists DPDPE (delta-agonist), U-62066 (kappa-agonist) and DALDA (mu-agonist) on the hypoxia-evoked response were investigated in both a whole-gland preparation and in isolated adrenal chromaffin cells using amperometry, whole-cell patch clamping and measurement of cytosolic [Ca(2+)]. "
06/01/1996 - "We found that BW373U86, like the peptide delta agonist, DPDPE ([D-Pen2, D-Pen5]-enkephalin), increases survival time of mice during lethal hypoxia. "
|1.||Ala(2)-MePhe(4)-Gly(5)- Enkephalin (DAGO)
|3.||delta Opioid Receptors (delta Opioid Receptor)
|4.||Morphine (MS Contin)
|5.||mu Opioid Receptors (mu Opioid Receptor)
|7.||Arachidonic Acid (Vitamin F)
|9.||Ala(2)- deltorphin II
|10.||D-Penicillamine (2,5)- Enkephalin